BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shehadeh F, Kalligeros M, Byrd K, Shemin D, Mylonakis E, Martin P, D'Agata EMC. Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis. Sci Rep 2020;10:14332. [PMID: 32868869 DOI: 10.1038/s41598-020-71205-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Hanif FM, Majid Z, Luck NH, Tasneem AA, Laeeq SM, Mubarak M. Revolution in the diagnosis and management of hepatitis C virus infection in current era. World J Hepatol 2022; 14(4): 647-669 [DOI: 10.4254/wjh.v14.i4.647] [Reference Citation Analysis]
2 Sise ME, McQuaid T, Martin P. Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease. Nephrol Dial Transplant 2021:gfab072. [PMID: 33848334 DOI: 10.1093/ndt/gfab072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 De A, Roy A, Verma N, Mishra S, Premkumar M, Taneja S, Singh V, Duseja A. Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: A systematic review and meta-analysis. Nephrology (Carlton) 2021. [PMID: 34453374 DOI: 10.1111/nep.13968] [Reference Citation Analysis]
4 Majd Jabbari S, Maajani K, Merat S, Poustchi H, Sepanlou SG. An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease. PLoS One 2021;16:e0246594. [PMID: 33566846 DOI: 10.1371/journal.pone.0246594] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]